Jubelirer Steven J, Arden Donna, Jones James W
CAMC Health Education and Research Institute, Charleston, USA.
W V Med J. 2005 Nov-Dec;101(6):256-7.
Patients with clotting disorders, including hemophilias A and B, and von Willebrand Disease generally receive pooled human blood products, and are at high risk for HIV-1 and hepatitis A, B and C viral infection. This retrospective study describes patients receiving treatment at a federally funded Hemophilia Treatment Center (HTC) from 1998 - 2002 and assesses the prevalence of viral infection. In addition, current rates of viral infection are compared to 1984-1996 rates.